FIELD: biotechnology.
SUBSTANCE: disclosed is an adeno-associated virus filler component, consisting of a nucleic acid of between 3,300 to 4,200 nucleotides in length.
EFFECT: said component reduces the inclusion of unintended genetic material in the adeno-associated viral (AAV) vector, does not contain enhancers, promoters, splicing regulators, non-coding RNA, anti-sense sequences or coding sequences and does not affect the activity of the expression cassette.
10 cl, 9 dwg, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROMOTER COMPOSITIONS | 2014 |
|
RU2742435C2 |
| THERAPEUTIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | 2015 |
|
RU2711147C2 |
| GENE EDITING OF DEEP INTRON MUTATIONS | 2016 |
|
RU2759335C2 |
| IMPROVEMENT OF CLINICAL PARAMETERS THROUGH FACTOR VIII EXPRESSION | 2019 |
|
RU2799048C2 |
| RNAi AGENT OPTION | 2018 |
|
RU2789647C2 |
| AVV VECTORS WITH IMPROVED Rep-CODING SEQUENCES USED IN INSECT CELL PRODUCTION SYSTEMS | 2007 |
|
RU2457252C2 |
| RECOMBINANT ADEN-ASSOCIATED VIRUS, WHICH IS HYBRID OF AAV9 AND AAVrh74 SEROTYPES, WITH REDUCED TROPISM FOR LIVER TISSUE | 2019 |
|
RU2812279C2 |
| GENE EDITING USING MODIFIED CLOSED-END DNA (ceDNA) | 2018 |
|
RU2811724C2 |
| MODIFICATION OF B-CELLS | 2018 |
|
RU2783116C2 |
| METHODS AND COMPOSITIONS FOR BRAIN DISEASES TREATMENT | 2014 |
|
RU2664471C2 |
